

## 12-2001: Anti-PD-1(Opdivo)(Nivolumab biosimilar) mAb

**Clonality :** Monoclonal

**Application :** ELISA,FACS

**Reactivity :** Human

**Isotype :** IgG4

### Description

Nivolumab (Opdivo), Pembrolizumab are both PD-1 inhibitors. PD-1 is a 'checkpoint' protein on immune cells that alerts them not to attack cells that express PD-L1. Some cancer cells express PD-L1, which enables them to “switch off” an immune system response. Monoclonal antibodies such as pembrolizumab and nivolumab block this signaling between PD-1 and PD-L1 and thereby reinforce the immune system response to tumor cells.

Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.

### Product Info

**Amount :** 100 µg

**Purification :** Purified from cell culture supernatant by affinity chromatography

**Content :** 0.5mg/ml, 200ul in PBS

**Storage condition :** Store at -20°C to -80°C (Avoid repeated freezing and thawing).

### Application Note

ELISA 1:5000-10000, FACS 1:100




Fig. 1: Coomassie Staining of Anti-PD-1(Opdivo)(Nivolumab biosimilar) mAb, 2ug of protein was loaded.




Figure 2: Flow Cytometry analysis: Anti-PD-1 (Opdivo) binds on the cell surface of PD-1 stable cell line (Cat No. 14-500ACL) using 0.5 ug of antibody. Green represents Anti-human IgG isotype control, red represents Anti-PD-1 (Opdivo)(Nivolumab biosimilar). FITC conjugated Goat anti-Human Fc was used as secondary antibody.